| General Information | |
|---|---|
| ZINC ID | ZINC000028701774 |
| Molecular Weight (Da) | 490 |
| SMILES | Cc1ccnc(OC(C)(C)C(=O)N[C@@H](C)[C@@H](Cc2ccc(OCCF)cc2)c2cccc(C#N)c2)c1 |
| Molecular Formula | C29F1N3O3 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 137.483 |
| HBA | 5 |
| HBD | 1 |
| Rotatable Bonds | 11 |
| Heavy Atoms | 36 |
| LogP | 5.9 |
| Activity (Ki) in nM | 0.4677 |
| Polar Surface Area (PSA) | 84.24 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.043 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.34 |
| Ilogp | 4.08 |
| Xlogp3 | 5.63 |
| Wlogp | 5.72 |
| Mlogp | 3.03 |
| Silicos-it log p | 6.5 |
| Consensus log p | 4.99 |
| Esol log s | -6 |
| Esol solubility (mg/ml) | 0.000489 |
| Esol solubility (mol/l) | 0.00000099 |
| Esol class | Poorly sol |
| Ali log s | -7.16 |
| Ali solubility (mg/ml) | 0.0000337 |
| Ali solubility (mol/l) | 6.88E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.65 |
| Silicos-it solubility (mg/ml) | 0.00000011 |
| Silicos-it solubility (mol/l) | 2.25E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.29 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 3 |
| Veber number of violations | 1 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 4.21 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.182 |
| Logd | 3.691 |
| Logp | 5.435 |
| F (20%) | 0.012 |
| F (30%) | 0.441 |
| Mdck | - |
| Ppb | 100.10% |
| Vdss | 1.744 |
| Fu | 1.34% |
| Cyp1a2-inh | 0.194 |
| Cyp1a2-sub | 0.796 |
| Cyp2c19-inh | 0.808 |
| Cyp2c19-sub | 0.281 |
| Cl | 7.867 |
| T12 | 0.044 |
| H-ht | 0.975 |
| Dili | 0.953 |
| Roa | 0.898 |
| Fdamdd | 0.866 |
| Skinsen | 0.025 |
| Ec | 0.003 |
| Ei | 0.007 |
| Respiratory | 0.951 |
| Bcf | 0.995 |
| Igc50 | 3.664 |
| Lc50 | 4.895 |
| Lc50dm | 5.223 |
| Nr-ar | 0.081 |
| Nr-ar-lbd | 0.005 |
| Nr-ahr | 0.021 |
| Nr-aromatase | 0.014 |
| Nr-er | 0.628 |
| Nr-er-lbd | 0.008 |
| Nr-ppar-gamma | 0.015 |
| Sr-are | 0.465 |
| Sr-atad5 | 0.01 |
| Sr-hse | 0.02 |
| Sr-mmp | 0.475 |
| Sr-p53 | 0.031 |
| Vol | 518.262 |
| Dense | 0.944 |
| Flex | 0.6 |
| Nstereo | 2 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 1 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.395 |
| Synth | 3.533 |
| Fsp3 | 0.345 |
| Mce-18 | 42 |
| Natural product-likeness | -0.955 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |